Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Benitec Biopharma Ltd ADR (BNTC)

Benitec Biopharma Ltd ADR (BNTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Benitec Biopharma Inc. to Participate in Upcoming Investor Conferences in December 2024

Benitec Biopharma will participate in investor conferences on December 4 and December 12, 2024, in New York.Quiver AI SummaryBenitec Biopharma Inc., a biotechnology company based in Hayward, California,...

BNTC : 11.85 (+3.13%)
Benitec Biopharma to Participate in Upcoming Investor Conferences in December

BNTC : 11.85 (+3.13%)
Insider Purchase: Director at $BNTC (BNTC) Buys 12,430 Shares

CAPITAL MANAGEMENT, LLC SUVRETTA, a director at $BNTC ($BNTC), bought 12,430 shares of the company on 11-19-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This...

BNTC : 11.85 (+3.13%)
Benitec Biopharma Reports Positive Interim Clinical Study Results for BB-301 in the Treatment of Oculopharyngeal Muscular Dystrophy

Benitec Biopharma reports promising interim results from BB-301 clinical trials for dysphagia, with ongoing patient enrollment and treatments.Quiver AI SummaryBenitec Biopharma Inc. announced positive...

BNTC : 11.85 (+3.13%)
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

BNTC : 11.85 (+3.13%)
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference

BNTC : 11.85 (+3.13%)
Benitec Biopharma Announces Updated Investor Webcast Information

BNTC : 11.85 (+3.13%)
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society

BNTC : 11.85 (+3.13%)
Why Novavax Stock Zoomed 13% Higher on Monday

A renewed fight against COVID-19 might be coming.

MRNA : 47.00 (+10.41%)
BNTC : 11.85 (+3.13%)
PFE : 27.37 (+1.79%)
JNJ : 145.99 (+1.62%)
NVAX : 11.14 (+14.14%)
Benitec’s (NASDAQ: BNTC) IND for BB-301 Cleared by FDA: A Milestone for OPMD Treatment

Benitec Biopharma Inc. (NASDAQ: BNTC), a leader in gene therapy, has announced that the U.S. Food and Drug Administration (FDA)

BLT.AX : 0.026 (-3.70%)
BNTC : 11.85 (+3.13%)

Barchart Exclusives

Is Unity Software Stock a Buy, Sell, or Hold on Roaring Kitty Rally?
Following a 30% drop in 2024, Unity Software’s stock has seen a brief rally in 2025 sparked by a Roaring Kitty tweet, but analysts remain cautious on U shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar